✓ Editorial reviews of U.S. telehealth programs · Prices and dates shown on each page · Educational only — not medical advice
Drug Reference

Ozempic

Released: Last reviewed:

Brand name for semaglutide, FDA-approved for type 2 diabetes mellitus. Same active ingredient as Wegovy and Rybelsus.

By Novo Nordisk
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 20, 2026 · This page is informational and does not constitute medical advice.

Ozempic overview

Brand name for semaglutide, FDA-approved for type 2 diabetes mellitus. Same active ingredient as Wegovy and Rybelsus.

Ozempic at a glance

Manufacturer
Novo Nordisk
FDA status
FDA-approved

Related pages

Key facts, checked November 20, 2026

The Ozempic injection label (effective July 30, 2026) covers blood-sugar control in adults with type 2 diabetes, lowering cardiovascular risk in adults with type 2 diabetes and heart disease, and lowering the risk of kidney decline and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, the use tested in FLOW (NEJM 2024). It is not approved for weight management; the weight-management semaglutide is Wegovy. The CMS fact sheet on 2027 negotiated prices lists a $274 Medicare price for a 30-day supply of Ozempic from January 1, 2027, which does not change cash prices.